Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

carbon C14 EGFR inhibitor ASP8273

A radioconjugate composed of ASP8273, an orally available, third-generation, mutant-selective, irreversible epidermal growth factor receptor (EGFR) inhibitor, labeled with the radioisotope carbon C 14, with potential use for evaluating the pharmacokinetic profile of ASP8273 during positron emission tomography (PET). Upon administration of carbon C 14 ASP8273, ASP8273 targets, covalently binds to and inhibits the activity of mutant forms of EGFR, including the T790M mutant form. Labeling of ASP8273 with the radioactive tracer carbon C 14 permits the evaluation of this agent's pharmacokinetic profile, including its absorption, distribution, metabolism, and excretion (ADME) using PET.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:[14C] EGFR inhibitor ASP8273
[14C]ASP8273
14C ASP8273
14C EGFR inhibitor ASP8273
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search